Genes and vaccines in alpha-1 antitrypsin deficiency
Treatments studied
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at how genetic differences in alpha-1 antitrypsin deficiency affect immune response to a pneumonia vaccine. It may help find better ways to prevent lung infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one copy of the Z gene for alpha-1 antitrypsin deficiency
- You have had either no COPD flare-ups in the past year or at least 2 flare-ups
- You have not had a Prevnar vaccine (pneumococcal conjugate) in the last 5 years
- You may have had the older pneumonia vaccine (pneumococcal polysaccharide) before
- You are not allergic or sensitive to the pneumococcal conjugate vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung health in women and girls in your community, including how their lungs work and what might affect them. By taking part, you help doctors learn more about women's breathing problems and how to improve care for women like you.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This study tests a one-time gene therapy called BEAM-302 that aims to fix the faulty gene causing alpha-1 antitrypsin deficiency (AATD), a condition that damages the lungs and liver. The goal is to improve AAT levels and slow or stop disease progression.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
This trial tests whether a new weekly injection form of alpha-1 antitrypsin replacement therapy (a protein your body lacks) works as well as the standard IV infusion you may currently receive. The goal is to offer a more convenient treatment option for people with alpha-1 antitrypsin deficiency (a genetic lung condition).
This trial tests whether giving an intravenous medication called alpha-1 antitrypsin can help people who are hospitalized with a sudden worsening of COPD (called an exacerbation). The medicine may help reduce lung inflammation and improve recovery.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.